Aktis Oncology Inc (AKTS)

Feb 10, 2026

2026 kicks off with $10.8B January financing haul - BioWorld MedTech

Feb 10, 2026

Feb 05, 2026

Merck veteran Perlmutter-led Eikon ‍Therapeutics valued at $860 million in Nasdaq debut - WTVB

Feb 05, 2026

Feb 05, 2026

Eikon’s $381M raise represents largest biopharma IPO in two years - BioWorld MedTech

Feb 05, 2026

Feb 05, 2026

IPO Tracker 2026: Eikon Clocks Largest IPO Since 2024, Generate, AgomAb Follow - BioSpace

Feb 05, 2026

Feb 04, 2026

Eikon Therapeutics raises $381M in IPO - Axios

Feb 04, 2026

Feb 04, 2026

Merck Veteran-Led Eikon Therapeutics Raises $381 Million in IPO - Bloomberg.com

Feb 04, 2026

Feb 04, 2026

Analysts Offer Insights on Healthcare Companies: Revvity (RVTY) and Aktis Oncology, Inc. (AKTS) - The Globe and Mail

Feb 04, 2026

Feb 03, 2026

Biopharma Co.'s Down-Round IPO May Signal More To Come - Law360

Feb 03, 2026

Feb 03, 2026

This GCI Liberty Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday - Benzinga

Feb 03, 2026

Feb 03, 2026

Aktis Oncology: Differentiated Miniprotein Radiopharma Platform Underpins Buy Rating and Multi-Billion Dollar Sales Potential - TipRanks

Feb 03, 2026

Jan 28, 2026

Merck veteran Perlmutter-led Eikon ‍Therapeutics eyes $908 million valuation in IPO - Reuters

Jan 28, 2026

Jan 28, 2026

Eikon ?Therapeutics targets $908 million valuation in US IPO - marketscreener.com

Jan 28, 2026

Jan 28, 2026

Eikon sets $274M goal for upcoming stock market debut - Fierce Biotech

Jan 28, 2026

Jan 27, 2026

Carvina Capital: Strong Demand Lifts Aktis IPO - Barchart.com

Jan 27, 2026

Jan 27, 2026

Aktis Oncology prices IPO at $18 per share - MSN

Jan 27, 2026

Jan 27, 2026

Should You Buy PICS Stock After the PicPay IPO? - Barchart.com

Jan 27, 2026

Jan 20, 2026

Why Revolution Medicines Stock Surged by 11% Today - AOL.com

Jan 20, 2026

Jan 19, 2026

Huge Insider Buying Now at This Insurance Giant and 2 Biotechs - AOL.com

Jan 19, 2026

Jan 19, 2026

Investors Scoop Up Shares in Key Insurance and Biotech Companies - finance.coin-turk.com

Jan 19, 2026

Jan 18, 2026

‘No reasons to own’: Software stocks sink on fear of new AI tool - The Japan Times

Jan 18, 2026

Jan 18, 2026

Assessing Aktis Oncology (AKTS) Valuation After IPO, NASDAQ Inclusion And Heavy Insider And Institutional Buying - Yahoo Finance

Jan 18, 2026

Jan 16, 2026

AKTS SEC FilingsAKTIS ONCOLOGY INC 10-K, 10-Q, 8-K Forms - Stock Titan

Jan 16, 2026

Jan 16, 2026

United StatesGoodwin Advises Aktis Oncology In Closing Of $365.4 Million Upsized Initial Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares - Mondaq

Jan 16, 2026

Jan 15, 2026

Wednesday Insider Activity: Mitsui’s $55.6M Berkley Buy Leads the Pack - Investing.com Nigeria

Jan 15, 2026

Jan 15, 2026

Wednesday Insider Activity: Mitsui’s $55.6M Berkley Buy Leads the Pack By Investing.com - Investing.com South Africa

Jan 15, 2026

Jan 15, 2026

Biotech Venture Limped Through 2025. A Brighter 2026 Beckons. - The Wall Street Journal

Jan 15, 2026

Jan 14, 2026

Insiders Make Bold Move as Key Players Double Down on Aktis Oncology - TipRanks

Jan 14, 2026

Jan 14, 2026

Aktis Oncology director Foley buys $4.19 million in shares By Investing.com - Investing.com India

Jan 14, 2026

Jan 14, 2026

Aktis Oncology: Mpm funds buy shares worth $20m By Investing.com - Investing.com Nigeria

Jan 14, 2026

Jan 14, 2026

Aktis Oncology: Mpm funds buy shares worth $20m - Investing.com

Jan 14, 2026

Jan 14, 2026

Aktis Oncology (AKTS) sees $20 million purchase by 10% owner - Investing.com South Africa

Jan 14, 2026

Jan 14, 2026

Aktis Oncology (AKTS) sees $20 million purchase by 10% owner By Investing.com - Investing.com Nigeria

Jan 14, 2026

Jan 14, 2026

Hedge Fund and Insider Trading News: Crispin Odey, Bill Ackman, Warren Buffett, Ray Dalio, ExodusPoint Capital, Saba Capital Management, Aktis Oncology Inc (AKTS), Warrior Met Coal Inc (HCC), and More - Insider Monkey

Jan 14, 2026

Jan 14, 2026

A Fresh IPO That Long-Term Investors Shouldn’t Ignore - Investing.com

Jan 14, 2026

Jan 14, 2026

A Fresh IPO That Long-Term Investors Shouldn't Ignore - Finviz

Jan 14, 2026

Jan 14, 2026

A Fresh IPO That Long-Term Investors Shouldn’t Ignore - Yahoo Finance

Jan 14, 2026

Jan 13, 2026

Aktis Oncology director Nodelman buys $40 million in shares By Investing.com - Investing.com Australia

Jan 13, 2026

Jan 13, 2026

Assessing Aktis Oncology (AKTS) Valuation After Recent Share Price Movement And Ongoing Losses - simplywall.st

Jan 13, 2026

Jan 13, 2026

Insider Stock Purchases: January 13, 2026 - Quiver Quantitative

Jan 13, 2026

Jan 13, 2026

Aktis Oncology Stock (AKTS) Opinions on Upsized IPO - Quiver Quantitative

Jan 13, 2026

Jan 13, 2026

Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times

Jan 13, 2026

Jan 13, 2026

Upcoming Events - FinancialContent

Jan 13, 2026

Jan 13, 2026

Tuesday 1/13 Insider Buying Report: AKTS, MSTR - Nasdaq

Jan 13, 2026

Jan 13, 2026

RTW Biotech Opp.Aktis announces $318 million IPO - Research Tree

Jan 13, 2026

Jan 12, 2026

Inside Biotech: Eikon Therapeutics joins IPO queue with late-stage oncology focus - Proactive financial news

Jan 12, 2026

Jan 12, 2026

Major Insider Moves Signal Growing Confidence in Aktis Oncology - TipRanks

Jan 12, 2026

Jan 12, 2026

Aktis Oncology director Nodelman buys $40 million in shares - Investing.com

Jan 12, 2026